Mikkael A. Sekeres, MD

home / authors / mikkael-a-sekeres-md

Articles

Dr Sekeres on Outcomes With Imetelstat in Transfusion-Dependent MDS

July 11th 2024

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia

Mikkael A. Sekeres, MD

July 1st 2024

Dr Sekeres discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Dr Sekeres on Outcomes from the ASTREON Trial in Low- to Intermediate-Risk MDS

Mikkael A. Sekeres, MD

June 26th 2024

Mikkael A. Sekeres, MD, discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial.

Dr Sekeres on the FDA Approval of Imetelstat in Lower-Risk MDS With Anemia

Mikkael A. Sekeres, MD

June 7th 2024

Mikkael A. Sekeres, MD, discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Dr. Sekeres on Staging Low- Versus High-Risk MDS

Mikkael A. Sekeres, MD

August 19th 2020

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Dr. Sekeres on the Need for Novel Combinations in Higher-Risk MDS/CMML and Low-Blast AML

Mikkael A. Sekeres, MD

June 4th 2020

Mikkael A. Sekeres, MD, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).